PURPOSE: Increased vascular endothelial growth factor (VEGF) receptor expression has been found at the sites of angiogenesis, particularly in tumor growth areas, as compared with quiescent vasculature. An increase in VEGF receptor-2 is associated with colon cancer progression. The in vivo detection of VEGF receptor is of interest for the purposes of studying basic mechanisms of carcinogenesis, making clinical diagnoses, and monitoring the efficacy of chemopreventive and therapeutic agents. In this study, a novel single chain (sc)VEGF-based molecular probe is utilized in the azoxymethane (AOM)-treated mouse model of colorectal cancer to study delivery route and specificity for disease. PROCEDURES: The probe was constructed by site-specific conjugation of a near-infrared fluorescent dye, Cy5.5, to scVEGF and detected in vivo with a dual-modality optical coherence tomography/laser-induced fluorescence (OCT/LIF) endoscopic system. A probe inactivated via excessive biotinylation was utilized as a control for nonreceptor-mediated binding. The LIF excitation source was a 633-nm He:Ne laser, and red/near-infrared fluorescence was detected with a spectrometer. OCT was used to obtain two-dimensional longitudinal tomograms at eight rotations in the distal colon. Fluorescence emission levels were correlated with OCT-detected disease in vivo. OCT-detected disease was verified with hematoxylin and eosin stained histology slides ex vivo. RESULTS: High fluorescence emission intensity from the targeted probe was correlated with tumor presence as detected using OCT in vivo and VEGFR-2 immunostaining on histological sections ex vivo. The inactivated probe accumulated preferentially on the surface of tumor lesions and in lymphoid aggregate tissue and was less selective for VEGFR-2. CONCLUSION: The scVEGF/Cy probe delivered via colonic lavage reaches tumor vasculature and selectively accumulates in VEGFR-2-positive areas, resulting in high sensitivity and specificity for tumor detection. The combination of OCT and LIF imaging modalities may allow the simultaneous study of tumor morphology and protein expression for the development of diagnostic and therapeutic methods for colorectal cancer.
PURPOSE: Increased vascular endothelial growth factor (VEGF) receptor expression has been found at the sites of angiogenesis, particularly in tumor growth areas, as compared with quiescent vasculature. An increase in VEGF receptor-2 is associated with colon cancer progression. The in vivo detection of VEGF receptor is of interest for the purposes of studying basic mechanisms of carcinogenesis, making clinical diagnoses, and monitoring the efficacy of chemopreventive and therapeutic agents. In this study, a novel single chain (sc)VEGF-based molecular probe is utilized in the azoxymethane (AOM)-treated mouse model of colorectal cancer to study delivery route and specificity for disease. PROCEDURES: The probe was constructed by site-specific conjugation of a near-infrared fluorescent dye, Cy5.5, to scVEGF and detected in vivo with a dual-modality optical coherence tomography/laser-induced fluorescence (OCT/LIF) endoscopic system. A probe inactivated via excessive biotinylation was utilized as a control for nonreceptor-mediated binding. The LIF excitation source was a 633-nm He:Ne laser, and red/near-infrared fluorescence was detected with a spectrometer. OCT was used to obtain two-dimensional longitudinal tomograms at eight rotations in the distal colon. Fluorescence emission levels were correlated with OCT-detected disease in vivo. OCT-detected disease was verified with hematoxylin and eosin stained histology slides ex vivo. RESULTS: High fluorescence emission intensity from the targeted probe was correlated with tumor presence as detected using OCT in vivo and VEGFR-2 immunostaining on histological sections ex vivo. The inactivated probe accumulated preferentially on the surface of tumor lesions and in lymphoid aggregate tissue and was less selective for VEGFR-2. CONCLUSION: The scVEGF/Cy probe delivered via colonic lavage reaches tumor vasculature and selectively accumulates in VEGFR-2-positive areas, resulting in high sensitivity and specificity for tumor detection. The combination of OCT and LIF imaging modalities may allow the simultaneous study of tumor morphology and protein expression for the development of diagnostic and therapeutic methods for colorectal cancer.
Authors: James B McNally; Nathaniel D Kirkpatrick; Lida P Hariri; Alexandre R Tumlinson; David G Besselsen; Eugene W Gerner; Urs Utzinger; Jennifer K Barton Journal: Appl Opt Date: 2006-05-01 Impact factor: 1.980
Authors: Lida P Hariri; Ziping Qiu; Alexandre R Tumlinson; David G Besselsen; Eugene W Gerner; Natalia A Ignatenko; Boris Povazay; Boris Hermann; Harald Sattmann; James McNally; Angelika Unterhuber; Wolfgang Drexler; Jennifer K Barton Journal: Cancer Biol Ther Date: 2007-08-12 Impact factor: 4.742
Authors: Maureen M Tedesco; Masahiro Terashima; Francis G Blankenberg; Zoia Levashova; Joshua M Spin; Marina V Backer; Joseph M Backer; Mien Sho; Eiketsu Sho; Michael V McConnell; Ronald L Dalman Journal: Arterioscler Thromb Vasc Biol Date: 2009-07-02 Impact factor: 8.311
Authors: Thomas D Wang; Shai Friedland; Peyman Sahbaie; Roy Soetikno; Pei-Lin Hsiung; Jonathan T C Liu; James M Crawford; Christopher H Contag Journal: Clin Gastroenterol Hepatol Date: 2007-10-23 Impact factor: 11.382
Authors: Francis G Blankenberg; Zoia Levashova; Susanta K Sarkar; John Pizzonia; Marina V Backer; Joseph M Backer Journal: Transl Oncol Date: 2010-02 Impact factor: 4.243
Authors: Hamid Pahlevaninezhad; Anthony M D Lee; Tawimas Shaipanich; Rashika Raizada; Lucas Cahill; Geoffrey Hohert; Victor X D Yang; Stephen Lam; Calum MacAulay; Pierre Lane Journal: Biomed Opt Express Date: 2014-08-06 Impact factor: 3.732
Authors: Photini F S Rice; Kevin G Ehrichs; Mykella S Jones; Hwudarw Chen; Chiu-Hsieh Hsu; Edward R Abril; Raymond B Nagle; David G Besselsen; Jennifer K Barton; Natalia A Ignatenko Journal: Cancer Prev Res (Phila) Date: 2017-11-08